## David Van Der Poorten

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11599010/publications.pdf

Version: 2024-02-01

36 papers 2,122 citations

430874 18 h-index 395702 33 g-index

36 all docs 36 docs citations

36 times ranked 3902 citing authors

#	Article	IF	CITATIONS
1	HBV vaccination and HBV infection induces HBV-specific natural killer cell memory. Gut, 2021, 70, gutjnl-2019-319252.	12.1	26
2	Hepatitis C Virus (HCV) Eradication With Interferon-Free Direct-Acting Antiviral-Based Therapy Results in KLRG1+ HCV-Specific Memory Natural Killer Cells. Journal of Infectious Diseases, 2021, 223, 1183-1195.	4.0	14
3	Endotrophin, a pro-peptide of Type VI collagen, is a biomarker of survival in cirrhotic patients with hepatocellular carcinoma. Hepatic Oncology, 2021, 8, HEP32.	4.2	9
4	Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery. Scientific Reports, 2021, 11, 14006.	3.3	9
5	Expansion of dysfunctional CD56â€CD16+ NK cells in chronic hepatitis B patients. Liver International, 2021, 41, 969-981.	3.9	12
6	<p>Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma – A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients</p> . Journal of Hepatocellular Carcinoma, 2020, Volume 7, 301-313.	3.7	17
7	KLRG1+ natural killer cells exert a novel antifibrotic function in chronic hepatitis B. Journal of Hepatology, 2019, 71, 252-264.	3.7	37
8	Subacute Upper GI Bleeding Due To Infected Aortic Graft with Aorto-Duodenal Fistula. Journal of Gastrointestinal Surgery, 2018, 22, 1987-1988.	1.7	0
9	Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma. PLoS ONE, 2016, 11, e0155800.	2.5	54
10	Epidemiological Trends in NASH as a Cause for Liver Transplant. Current Hepatology Reports, 2016, 15, 67-74.	0.9	8
11	MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Nature Communications, 2016, 7, 12757.	12.8	104
12	Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology, 2016, 64, 34-46.	7.3	83
13	Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease. Journal of Clinical Neuroscience, 2016, 25, 41-45.	1.5	38
14	Small bowel varices secondary to chronic superior mesenteric vein thrombosis in a patient with heterozygous Factor V Leiden mutation: a case report. Journal of Medical Case Reports, 2015, 9, 210.	0.8	4
15	Feasibility and Safety of Overtubes for PEG-Tube Placement in Patients with Head and Neck Cancer. Gastroenterology Research and Practice, 2015, 2015, 1-7.	1.5	6
16	Oily fish, coffee and walnuts: Dietary treatment for nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2015, 21, 10621.	3.3	38
17	Adiponectin Reduces Hepatic Stellate Cell Migration by Promoting Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Secretion. Journal of Biological Chemistry, 2015, 290, 5533-5542.	3.4	50
18	IFNL3 mediates interaction between innate immune cells: Implications for hepatitis C virus pathogenesis. Innate Immunity, 2014, 20, 598-605.	2.4	15

#	Article	IF	Citations
19	Oxidative stress is closely associated with insulin resistance in genotypes 1 and 3 chronic hepatitis C. Hepatology International, 2013, 7, 516-523.	4.2	1
20	Non-alcoholic fatty liver disease-related hepatocellular carcinoma: a sleeping tiger in the Asia Pacific. Hepatology International, 2013, 7, 823-832.	4.2	10
21	Visceral adiposity in gastrointestinal and hepatic carcinogenesis. Cancer Letters, 2013, 330, 1-10.	7.2	66
22	Hepatic fat loss in advanced nonalcoholic steatohepatitis: Are alterations in serum adiponectin the cause?. Hepatology, 2013, 57, 2180-2188.	7.3	136
23	NT-proBNP Changes in Patients with Ascites during Large Volume Paracentesis. ISRN Hepatology, 2013, 2013, 1-7.	0.9	1
24	Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2012, 57, 392-398.	3.7	53
25	The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study. Hepatology, 2011, 54, 1208-1216.	7.3	399
26	Paraneoplastic Hepatic Dysfunction in Metastatic Prostate Cancer: The Role of Cytokine Dysregulation. Journal of Clinical Oncology, 2011, 29, e21-e23.	1.6	12
27	Chronic Hepatitis C Is Associated With Peripheral Rather Than Hepatic Insulin Resistance. Gastroenterology, 2010, 138, 932-941.e3.	1.3	124
28	Hepatitis C Virus Induces the Cannabinoid Receptor 1. PLoS ONE, 2010, 5, e12841.	2.5	46
29	Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology, 2009, 49, 1926-1934.	7.3	144
30	Reply:. Hepatology, 2009, 50, 327-328.	7.3	0
31	Visceral fat: A key mediator of steatohepatitis in metabolic liver disease. Hepatology, 2008, 48, 449-457.	7.3	522
32	Reply:. Hepatology, 2008, 48, 1729-1729.	7.3	0
33	Disease-Specific Mechanisms of Fibrosis: Hepatitis C Virus and Nonalcoholic Steatohepatitis. Clinics in Liver Disease, 2008, 12, 805-824.	2.1	28
34	Prevalence of and risk factors for hepatitis C in Aboriginal and nonâ€Aboriginal adolescent offenders. Medical Journal of Australia, 2008, 188, 610-614.	1.7	18
35	Liver disease in adolescents: A cohort study of high-risk individuals. Hepatology, 2007, 46, 1750-1758.	7.3	33
36	Current and novel therapies for the treatment of nonalcoholic steatohepatitis. Hepatology International, 2007, 1, 343-354.	4.2	5